scholarly article | Q13442814 |
P356 | DOI | 10.1046/J.1365-2036.2003.01545.X |
P953 | full work available at URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01545.x |
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01545.x | ||
https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01545.x | ||
P698 | PubMed publication ID | 12694084 |
P5875 | ResearchGate publication ID | 10806058 |
P2093 | author name string | U. Ladabaum | |
P2860 | cites work | Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis | Q28191273 |
EuroQol--a new facility for the measurement of health-related quality of life | Q29547873 | ||
Management of the irritable bowel syndrome | Q31941893 | ||
A general health policy model: update and applications | Q33717420 | ||
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial | Q33896354 | ||
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis | Q33923878 | ||
Lotronex and the FDA: a fatal erosion of integrity | Q33948603 | ||
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome | Q33960506 | ||
Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials | Q33969643 | ||
Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review | Q34030004 | ||
Costs of care for irritable bowel syndrome patients in a health maintenance organization | Q34103131 | ||
Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness | Q34299363 | ||
Health-related quality of life among persons with irritable bowel syndrome: a systematic review | Q34657373 | ||
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations | Q34714134 | ||
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome | Q39416131 | ||
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients | Q39434734 | ||
Recommendations of the Panel on Cost-effectiveness in Health and Medicine | Q41145868 | ||
Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results | Q41434879 | ||
Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study | Q43406988 | ||
The FDA and The Lancet: an exchange | Q43706110 | ||
The impact of irritable bowel syndrome on health-related quality of life | Q46485395 | ||
The burden of selected digestive diseases in the United States | Q50113541 | ||
The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors | Q50126848 | ||
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. | Q53435090 | ||
Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. | Q53486440 | ||
Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities | Q57696073 | ||
Utilities and quality-adjusted life years | Q69463744 | ||
Impact of irritable bowel syndrome on quality of life | Q71835032 | ||
Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease | Q73363000 | ||
American Gastroenterological Association medical position statement: irritable bowel syndrome | Q73404058 | ||
The FDA and The Lancet: an exchange | Q74367838 | ||
Physicians' diagnostic judgments and treatment decisions for acute otitis media in children | Q74496859 | ||
The FDA and The Lancet: an exchange | Q93961585 | ||
The FDA and The Lancet: an exchange | Q93961588 | ||
The FDA and The Lancet: an exchange | Q93961591 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | alosetron | Q416463 |
pharmacotherapy | Q701216 | ||
P304 | page(s) | 1021-1030 | |
P577 | publication date | 2003-04-01 | |
P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
P1476 | title | Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications | |
P478 | volume | 17 |
Q38310117 | 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders |
Q34649076 | Alosetron and irritable bowel syndrome |
Q33274027 | CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection |
Q34489390 | Costs of irritable bowel syndrome in the UK and US. |
Q34618925 | Gut hormones: emerging role in immune activation and inflammation. |
Q45138901 | Quantitative benefit-risk assessment using only qualitative information on utilities. |
Q37944318 | Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries |
Q34317503 | Serotonin and GI Disorders: An Update on Clinical and Experimental Studies |
Q35178813 | Subjective food hypersensitivity: assessment of enterochromaffin cell markers in blood and gut lavage fluid |
Q38032174 | The chronic gastrointestinal consequences associated with campylobacter |